Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
for Solid Tumors
Sites in New York +16 more locations
Sponsor: ORIC Pharmaceuticals
Sex: All·Age: 18+
Code: NCT05315700·Phase 1, Phase 2·Recruiting·Listed Apr 2022